Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: The role of aldosterone blockade in murine lupus nephritis. | Available online http content 10 1 R5 Research article The role of aldosterone blockade in murine lupus nephritis Seetha U Monrad1 Paul D Killen2 Marc R Anderson1 Amanda Bradke1 and Mariana J Kaplan1 Division of Rheumatology Internal Medicine University of Michigan Medical School Ann Arbor Michigan 48109 USA 2Department of Pathology University of Michigan Medical School Ann Arbor Michigan 481 09 USA Corresponding author Mariana J Kaplan makaplan@ Received 22 Sep 2007 Revisions requested 26 Nov 2007 Revisions received 11 Dec 2007 Accepted 15 Jan 2008 Published 15 Jan 2008 Arthritis Research Therapy 2008 10 R5 doi 1 ar2353 This article is online at http content 10 1 R5 2008 Monrad et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Background The purpose of this study was to examine the effect of aldosterone receptor blockade on the immunopathogenesis and progression of nephritis in the NZB X NZW F1 murine lupus model. Methods Female NZB W F1 mice 11 weeks old were treated daily with 25 or 50 mg kg oral spironolactone or vehicle. Proteinuria renal function and serum autoantibody levels were monitored. Renal histopathology immune complex deposition and immunohistochemistry were analyzed at various time points. Targeted microarray analysis was performed on renal tissue with subsequent real-time PCR analysis of several differentially expressed genes. Results Treatment with spironolactone was well tolerated by the mice throughout the course of their disease progression with no significant differences in azotemia or serum potassium levels between vehicle-treated and spironolactone-treated animals. By 36 weeks of age fewer spironolactone-treated .
